Immunome, Inc. (IMNM) vs Trevi Therapeutics, Inc. (TRVI)
A side-by-side comparison of Immunome, Inc. and Trevi Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
IMNM
Immunome, Inc.
$19.85HealthcareDelayed quote: Oct 6, 2026, 3:05 PM EDT
TRVI
Trevi Therapeutics, Inc.
$13.36HealthcareDelayed quote: Oct 6, 2026, 3:05 PM EDT
Total return — IMNM vs TRVI
growth of $100 · dividends reinvested · last 6yIMNM +57.4% (+7.9%/yr)TRVI +250.9% (+23.3%/yr)TRVI compounded faster over this window
IMNM TRVI
IMNM vs TRVI: by the numbers
- •IMNM is the larger company ($1.90B vs $1.90B market cap).
- •Both run net losses; TRVI's is the smaller (0.00% vs -3059.99% net margin).
Metrics side by side
Valuation
| Metric | IMNM | TRVI |
|---|---|---|
| P/B ratio | 3.61 | 5.90 |
Profitability
| Metric | IMNM | TRVI |
|---|---|---|
| Gross margin | 57.43% | 0.00% |
| Operating margin | -3084.76% | 0.00% |
| Net margin | -3059.99% | 0.00% |
| ROE | -48.43% | -15.90% |
| ROIC | -51.06% | -18.51% |
Growth (annualized)
| Metric | IMNM | TRVI |
|---|---|---|
| Total return CAGR (5Y) | 2.88% | 61.74% |
Frequently asked
- How have IMNM and TRVI total returns compared?
- Over the past 5 years, IMNM delivered 2.88% and TRVI delivered 61.74% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.